Clinical cases of eculizumab use as a part of complex therapy in patients with severe COVID‐19: 615-038:578.834.1

Abstract

Summary. Background. In the past two years, the incidence of the novel coronavirus (CoV) infection COVID-19 (COrona VIrus Disease-2019) has been a serious problem for the global community. Considering these circumstances, new molecules and already registered drugs that have proven their effectiveness in other diseases, began to be actively used in COVID-19 treatment. Objectives: to assess the efficacy of eculizumab in patients with severe COVID-19. Patients/Methods. Three clinical cases of eculi- zumab use as a part of complex therapy in patients with severe COVID-19 have been analyzed. To assess the treatment efficacy, the main clinical and laboratory parameters and indicators of inflammatory process in coronavirus infection were monitored (clinical blood analysis, biochemical blood test, levels of ferritin, C-reactive protein, interleukin-6, lactate dehydrogenase and membrane attack complex). Results. Under the therapy we found the reduction of concentration of the main inflammation markers relative to the initial values. Conclusions. Complex therapy with eculizumab facilitates the course of the disease, reduces the stay dura- tion of patients in the intensive care unit, shortens the period of artificial lung ventilation, thereby reducing the mortality rate.

References:

1. Bakirov B.A., Kudlay D.A., Pavlov V.N. Eculizumab in the treatment of complement system disorders including paroxysmal nocturnal Voprosy gematologii/onkologii i immunopatologii v pediatrii. 2020;19(2):193–9. (In Russ.). DOI: 10.24287/1726–1708– 2020–19–2–193–199. 

2. Botto M., Kirschfink M., Macor P. et al. Complement in human diseases: lessons from complement deficiencies. Mol Immunol. 2009;46(14):2774–83. DOI: 10.1016/j.molimm.2009.04.029. 

3. Blazina S., Debeljak M., Kosnik M. et al. Functional complement analysis can predict genetic testing results and long‐term out‐ come in patients with complement deficiencies. Front Immunol. 2018;9:500. DOI: 10.3389/fimmu.2018.00500. 

4. De Cordoba S.R. Complement genetics and susceptibility to inflammatory disease. Lessons from genotype‐phenotype cor‐ Immunobiology. 2016;221(6):709–14. DOI: 10.1016 / j. imbio.2015.05.015. 

5. Grumach A.S., Kirschfink M. Are complement deficiencies really rare? Overview on prevalence, clinical importance and modern diagnostic approach. Mol Immunol. 2014;61(2):110–7. DOI: 10.1016/j. 2014.06.030. 
6. Bobkova S.S., Zhukov A.A., Protsenko D.N. et al. Comparative study of monoclonal anti‐IL6 antibodies in severe new corona‐ virus disease COVID‐19 patients. Retrospective cohort study. Vest­ nik intensivnoj terapii imeni A.I. Saltanova. 2021;(1):69–76. (In Russ.). DOI: 10.21320/1818–474X‐2021–1–69–76. 

7. Kulagin A.D., Lisukov I.A., Ptushkin V.V. et al. National clinical guidelines for the diagnosis and treatment of paroxysmal noctur‐ nal hemoglobinuria. Onkogematologiya. 2014;9(2):20–8. (In Russ.). DOI: 10.17650/1818–8346–2014–9–2–20–28. 

8. Devos T., Meers S., Boeckx N. et al. Diagnosis and management of PNH: Review and recommendations from a Belgian expert panel. Eur J Haematol. 2018;101(6):737–49. DOI: 10.1111/ejh.13166. 
9.   
Kuznik B.I, SturovV.G., Levshin N.Yu. et al. Hemorrhagic and thrombotic diseases and syndromes in children and adolescents: pathogenesis, clinical picture, diagnosis, therapy and prevention. Novosibirsk: Nauka, 2018. 524 pp. (In Russ.). 

10. Hillmen P., Muus P., Roth A. et al. Long‐term safety and efficacy of sustained eculizumab treatment in patients with paroxys‐ mal nocturnal haemoglobinuria. Br J Haematol. 2013;162(1):62– 73. DOI: 10.1111/bjh.12347. 

11. Kulagin A., Klimova O., Rudakova T. et al. Benefits and limitations of long‐term eculizumab treatment for paroxysmal nocturnal hemoglobinuria (PNH): Real‐world data from large cohort study in Russia. Blood. 2018;132(Suppl 1):2589. DOI: 10.1182/blood‐2018– 99–120139. 

12. Emirova Кh.M., Orlova O.M., Muzurov A.L. et al. The experience of using Elizaria® for atypical hemolytic uremic syndrome. Pedi­ atriya. Zhurnal imeni G.N. Speranskogo. 2019;98(5):225–9. (In Russ.). DOI: 10.24110/0031–403X‐2019–98–5–225–229.
13. Lavrishcheva I.V., Jakovenko A.A., Kudlay D.A. A case report of atypical hemolytic‐uremic syndrome treatment with the first Russian eculizumab in adult patient. Urol Nephrol Open Access J. 2020;8(2):37–40.
14. Ivanov R., Sekaryova G., Kravtsova O. et al. Rules for conducting research on biosimilar drugs (biosimilars). Pharmacokinetics and Pharmacodynamics. 2014;(1):21–36. (In Russ.).
15. Ptushkin V.V., Kulagin A.D., Lukina E.A. et al. Results of phase Ib open multicenter clinical trial of the safety, pharmacokinet‐ ics and pharmacodynamics of first biosimilar of eculizumab in untreated patients with paroxysmal nocturnal hemoglo‐ binuria during induction of therapy. Terapevticheskij arhiv. 2020;92(7):77–84. (In Russ.). DOI: 10.26442/00403660.2020.0 7.000818.
16. Kulagin A., Ptushkin V., Lukina E. et al. Phase III clinical trial of Elizaria® and Soliris® in adult patients with paroxysmal noctur‐ nal hemoglobinuria: results of comparative analysis of efficacy, safety, and pharmacological data. Blood. 2019;134(Suppl 1):3748. DOI: 10.1182/blood‐2019–125693.
17. Guo R.‐, Ward P.A. Role of C5a in inflammatory responses. Annu Rev Immunol. 2005;23:821–52. DOI: 10.1146/annurev.immu‐ nol.23.021704.115835.
18. Song Y.G., Shin H.S. COVID‐19, а clinical syndrome manifesting as hypersensitivity pneumonitis. Infect Chemother. 2020;52(1):110–2. DOI: 10.3947/ic.2020.52.1.110.
19. Bobkova S.S., Zhukov A.A., Protsenko D.N. et al. Critical appraisal of the “cytokine storm” concept in new coronavirus disease COVID‐19. Review. Vestnik intensivnoj terapii imeni A.I. Saltanova.. 2021;(1):57–68. (In Russ.). DOI: 10.21320/1818–474X‐2021–1–57–68.

1. Dubois E. A., Cohen A. F. Eculizumab. Br J Clin Pharmacol. 2009;68(3):318–9. DOI: 10.1111/j.1365–2125.2009.03491.x.
2. Sahebnasagh A., Avan R., Saghafi F. et al. Pharmacological treat‐ ments of COVID‐ Pharmacol Rep. 2020;72(6):1446–78. DOI: 10.1007/s43440–020–00152–9.
3. Diurno F., Numis F. G., Porta G. et al. Eculizumab treatment in patients with COVID‐19: preliminary results from real life ASL Napoli 2 Nord experience. Eur Rev Med Pharmacol Sci. 2020;24(7):4040–7. DOI: 10.26355/eurrev_202004_20875.
4. Annanea D., Heming N., Grimaldi‐Bensouda L. et al. Eculizumab as an emergency treatment for adult patients with severe COVID‐19 in the intensive care unit: A proof‐of‐concept study. EClinicalMe­ dicine. 2020;28:100590. DOI: 10.1016/j.eclinm.2020.100590.
5. Kudlay D.A., Bakirov B.A., Pavlov V.N. The nature of the mono‐ clonal antibody eculizumab and its potential for corona‐virus infection COVID‐19. Tromboz, gemostaz i reologiya. 2020;(2):27– 32. (In Russ.). DOI: 10.25555/THR.2020.2.0915.